[8-K] Aveanna Healthcare Holdings, Inc. Reports Material Event
Aveanna Healthcare Holdings Inc. (AVAH)10,000,000 shares of common stock at $9.00 per share. The underwriters were led by Jefferies and J.P. Morgan, and the transaction closed on October 23, 2025.
The selling stockholders also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares. Aveanna did not issue any shares in this sale and did not receive proceeds, as all shares were sold by existing holders.
Aveanna Healthcare Holdings Inc. (AVAH)) ha riportato che soci venditori affiliati a J.H. Whitney Equity Partners VII hanno completato un'offerta secondaria di 10.000.000 azioni ordinarie a 9,00 USD a azione. Gli underwriter erano guidati da Jefferies e J.P. Morgan, e l'operazione si è chiusa il 23 ottobre 2025.
I soci venditori hanno anche concesso agli underwriter una opzione di 30 giorni per acquistare fino a ulteriori 1.500.000 azioni. Aveanna non ha emesso alcuna azione in questa vendita e non ha ricevuto proventi, poiché tutte le azioni sono state vendute dai detentori esistenti.
Aveanna Healthcare Holdings Inc. (AVAH)) informó que accionistas vendedores afiliados a J.H. Whitney Equity Partners VII completaron una oferta secundaria de 10,000,000 de acciones ordinarias a 9,00 USD por acción. Los underwriters fueron liderados por Jefferies y J.P. Morgan, y la operación se cerró el 23 de octubre de 2025.
Los vendedores también otorgaron a los underwriters una opción de 30 días para comprar hasta 1,500,000 acciones adicionales. Aveanna no emitió ninguna acción en esta venta y no recibió ingresos, ya que todas las acciones fueron vendidas por los titulares existentes.
Aveanna Healthcare Holdings Inc. (AVAH))는 J.H. Whitney Equity Partners VII에 소속된 매각 주주들이 1,000만 주의 보통주를 주당 $9.00에 2차 매도를 완료했다고 발표했습니다. 주간사는 Jefferies, J.P. Morgan이 이끌었고, 거래는 2025년 10월 23일에 마감되었습니다.
매각 주주들은 또한 주간사에게 30일 옵션으로 추가로 1,500,000 주를 구매할 수 있는 권리를 부여했습니다. Aveanna는 이 매도에서 어떤 주식도 발행하지 않았으며 수익도 받지 못했습니다, 모든 주식은 기존 보유자에 의해 팔렸기 때문입니다.
Aveanna Healthcare Holdings Inc. (AVAH)) a annoncé que des actionnaires vendeurs affiliés à J.H. Whitney Equity Partners VII ont réalisé une offre secondaire de 10 000 000 actions ordinaires au prix de 9,00 USD par action. Les souscripteurs étaient menés par Jefferies et J.P. Morgan, et l'opération a été clôturée le 23 octobre 2025.
Les actionnaires vendeurs ont également accordé aux souscripteurs une option de 30 jours pour acheter jusqu'à 1 500 000 actions supplémentaires. Aveanna n'a émis aucune action lors de cette vente et n'a pas reçu de produits, car toutes les actions ont été vendues par les détenteurs existants.
Aveanna Healthcare Holdings Inc. (AVAH)) berichtete, dass mit J.H. Whitney Equity Partners VII verbundene verkaufende Aktionäre eine Sekundärofferierung von 10.000.000 Aktien Stammaktien zu 9,00 USD pro Aktie abgeschlossen haben. Die Zeichner wurden von Jefferies und J.P. Morgan geführt, und die Transaktion wurde am 23. Oktober 2025 abgeschlossen.
Die verkaufenden Aktionäre gewährten den Underwritern außerdem eine 30-Tage-Option, bis zu zusätzlichen 1.500.000 Aktien zu kaufen. Aveanna gab in diesem Verkauf keine Aktien aus und erhielt keinen Erlös, da alle Aktien von bestehenden Inhabern verkauft wurden.
Aveanna Healthcare Holdings Inc. (AVAH)) أعلنت أن المساهمين البائعين المتحالفين مع J.H. Whitney Equity Partners VII أكملوا عرضه الثانوي لـ 10,000,000 سهم من الأسهم العادية بسعر 9.00 دولار للسهم. وكان المصرفيون المستلمون بقيادة Jefferies و J.P. Morgan، وأُغلِق الصفقة في 23 أكتوبر 2025.
كما منح المساهمون البائعون المصرفيين المستلمين خيار 30 يوماً لشراء حتى 1,500,000 سهم إضافية. لم تصدر Aveanna أي أسهم في هذا البيع ولم تتلق أي عائد، حيث بيع جميع الأسهم من قبل المالكين القائمين.
- None.
- None.
Aveanna Healthcare Holdings Inc. (AVAH)) ha riportato che soci venditori affiliati a J.H. Whitney Equity Partners VII hanno completato un'offerta secondaria di 10.000.000 azioni ordinarie a 9,00 USD a azione. Gli underwriter erano guidati da Jefferies e J.P. Morgan, e l'operazione si è chiusa il 23 ottobre 2025.
I soci venditori hanno anche concesso agli underwriter una opzione di 30 giorni per acquistare fino a ulteriori 1.500.000 azioni. Aveanna non ha emesso alcuna azione in questa vendita e non ha ricevuto proventi, poiché tutte le azioni sono state vendute dai detentori esistenti.
Aveanna Healthcare Holdings Inc. (AVAH)) informó que accionistas vendedores afiliados a J.H. Whitney Equity Partners VII completaron una oferta secundaria de 10,000,000 de acciones ordinarias a 9,00 USD por acción. Los underwriters fueron liderados por Jefferies y J.P. Morgan, y la operación se cerró el 23 de octubre de 2025.
Los vendedores también otorgaron a los underwriters una opción de 30 días para comprar hasta 1,500,000 acciones adicionales. Aveanna no emitió ninguna acción en esta venta y no recibió ingresos, ya que todas las acciones fueron vendidas por los titulares existentes.
Aveanna Healthcare Holdings Inc. (AVAH))는 J.H. Whitney Equity Partners VII에 소속된 매각 주주들이 1,000만 주의 보통주를 주당 $9.00에 2차 매도를 완료했다고 발표했습니다. 주간사는 Jefferies, J.P. Morgan이 이끌었고, 거래는 2025년 10월 23일에 마감되었습니다.
매각 주주들은 또한 주간사에게 30일 옵션으로 추가로 1,500,000 주를 구매할 수 있는 권리를 부여했습니다. Aveanna는 이 매도에서 어떤 주식도 발행하지 않았으며 수익도 받지 못했습니다, 모든 주식은 기존 보유자에 의해 팔렸기 때문입니다.
Aveanna Healthcare Holdings Inc. (AVAH)) a annoncé que des actionnaires vendeurs affiliés à J.H. Whitney Equity Partners VII ont réalisé une offre secondaire de 10 000 000 actions ordinaires au prix de 9,00 USD par action. Les souscripteurs étaient menés par Jefferies et J.P. Morgan, et l'opération a été clôturée le 23 octobre 2025.
Les actionnaires vendeurs ont également accordé aux souscripteurs une option de 30 jours pour acheter jusqu'à 1 500 000 actions supplémentaires. Aveanna n'a émis aucune action lors de cette vente et n'a pas reçu de produits, car toutes les actions ont été vendues par les détenteurs existants.
Aveanna Healthcare Holdings Inc. (AVAH)) berichtete, dass mit J.H. Whitney Equity Partners VII verbundene verkaufende Aktionäre eine Sekundärofferierung von 10.000.000 Aktien Stammaktien zu 9,00 USD pro Aktie abgeschlossen haben. Die Zeichner wurden von Jefferies und J.P. Morgan geführt, und die Transaktion wurde am 23. Oktober 2025 abgeschlossen.
Die verkaufenden Aktionäre gewährten den Underwritern außerdem eine 30-Tage-Option, bis zu zusätzlichen 1.500.000 Aktien zu kaufen. Aveanna gab in diesem Verkauf keine Aktien aus und erhielt keinen Erlös, da alle Aktien von bestehenden Inhabern verkauft wurden.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 21, 2025, Aveanna Healthcare Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and among the Company, certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC (the “Selling Stockholders”) and Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (the “Underwriters”), providing for the offer and sale by the Selling Stockholders (the “Secondary Offering”) of 10,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $9.00 per share. In addition, the Selling Stockholders granted the Underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company’s Common Stock. The Secondary Offering closed on October 23, 2025. The Company did not issue or sell any Common Stock in the Secondary Offering and did not receive any proceeds from the Secondary Offering.
The foregoing description of the Underwriting Agreement is qualified in its entirety by the terms of such agreement, which is incorporated herein by reference and attached to this report as Exhibit 1.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
1.1 |
|
Underwriting Agreement, dated October 21, 2025, by and among Aveanna Healthcare Holdings Inc., the selling stockholders named therein, and Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein. |
5.1 |
|
Opinion of King & Spalding LLP |
23.1 |
|
Consent of King & Spalding LLP (included in Exhibit 5.1 above) |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
AVEANNA HEALTHCARE HOLDINGS INC. |
|
|
|
|
Date: |
October 23, 2025 |
By: |
/s/ Matthew Buckhalter |
|
|
|
Matthew Buckhalter |
FAQ
What did Aveanna Healthcare (AVAH) announce in this 8-K?
Did Aveanna receive any proceeds from the secondary offering?
Was there an underwriters’ option included?
When did the secondary offering close?
Who were the lead underwriters for AVAH’s secondary offering?
Who sold the shares in the AVAH transaction?
What securities were involved in the sale?
